



## Dr. med. Salome Riniker

### Contact

Dr. med. Salome Riniker  
Rorschacherstrasse 95  
9007 St.Gallen  
Switzerland

T +41 71 494 19 77  
Salome.Riniker@kssg.ch

### Homepage

[www.kssg.ch/brustzentrum](http://www.kssg.ch/brustzentrum)

### Units

Medizinische Onkologie und Hämatologie, Brustzentrum St.Gallen

### Profile Function

chief of service

## Publications (4)

Stoll S, Unger S, Azzarello-Burri S, Chappuis P, Graffeo R, Pichert G, Röthlisberger B, Taban F, Riniker S. Update Swiss guideline for counselling and testing for predisposition to breast, ovarian, pancreatic and prostate cancer. *Swiss Med Wkly* 2021; 151:w30038.

Zweifel M, Sessa C, Schoenfeld W, Tapia C, Brauchli P, Hawle H, Pilop C, Rothgiesser K, Bigler M, Pagani O, von Moos R, Weder P, Riniker S, Thürlimann B. Phase I trial of the androgen receptor modulator CR1447 in breast cancer patients. *Endocr Connect* 2017; 6:549-556.

Hitz F, Klingbiel D, Omlin A, Riniker S, Zerz A, Cerny T. Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial. *Ann Hematol* 2011; 91:613-20.

Riniker S, Riniker S, Köberle D. (Neo-) Adjuvante Therapien des Rektumkarzinoms: Neue Strategien. *Schweizer Zeitschrift für Onkologie* 2007; 3:25-28.

## Projects (10)

**Eribulin as 1st line treatment in elderly patients ( $\geq 70$  years) with advanced breast cancer: a multicenter phase II trial**

*Clinical Studies - Aug 11, 2015 - Jun 30, 2019*

*Automatically Closed*

**Phase III international, randomized study of Trabectedin plus Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin plus PLD in patients with ovarian cancer progressing within 6-12 months of last platinum**

*Clinical Studies - Jul 4, 2014 - Apr 16, 2021*

*Automatically Closed*

**A Multicenter Phase III Randomized study with second line chemotherapy plus or minus Bevacizumab in patients with Platinum sensitive Epithelial ovarian cancer recurrence after a Bevacizumab/chemotherapy first line**

*Clinical Studies - May 27, 2014 - Jun 27, 2016*

*Automatically Closed*

**A Phase I and stratified, multicenter Phase II trial of trans-dermal CR1447 (4-OH-testosterone) in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer**

*Clinical Studies - Apr 14, 2014 - Jul 23, 2017*

*Automatically Closed*

**A randomized phase II study evaluating different schedules of nab-Paclitaxel in metastatic breast cancer**

*Clinical Studies - Oct 21, 2013 - Apr 30, 2016*

*Completed*

**A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer**

*Clinical Studies - May 1, 2013 - May 1, 2019*

*Automatically Closed*

**SAKK 22/10: A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer**

*Clinical Studies - Apr 29, 2013 - Jun 27, 2015*

*Automatically Closed*

**Clinical and biological characterization of Male Breast Cancer: an international retrospective EORTC, BIG and NABCG intergroup study**

*Clinical Studies - Dec 19, 2012 - Mar 1, 2013*

*Automatically Closed*

**A randomized, multicenter, phase III open-label study of the efficacy and safety of Trastuzumab-MCC-DM1 vs. Capecitabine and Lapatinib in patients with HER2-positive locally advanced or metastatic breast cancer who have received prior Trastuzumab-based therapy**

*Clinical Studies - Oct 20, 2009 - Jun 30, 2011*

*Completed*

**Ein Phase III Studienprogramm zur Kombination von Bevacizumab, Everolimus (RAD001) oder Lapatinib mit einer neoadjuvanten Chemotherapie bei primärem Mammakarzinom**

*Clinical Studies - Jun 30, 2009 - Jun 30, 2012*

*Completed*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch